Human Immunodeficiency Virus - Associated Lymphomas: a Neglected Domain

Overview

Journal N Am J Med Sci

Specialty General Medicine

Date 2013 Sep 11

PMID 24020054

Citations 2

Authors

Nagesh Tatero Sirsath

Lakshmaiah Kuntejowdahalli Channaviriappa

Lokesh Kadabur Nagendrappa

Lokanatha Dasappa

Vishwanath Sathyanarayanan

Govind Babu Kanaka Setty

Affiliations

Soon will be listed here.

Abstract

Background: Human immunodeficiency virus (HIV) associated lymphoma is an important public health concern; however, the epidemiological data available from India is sparse.

Aims: The present study was carried out at a tertiary cancer care center in South India to analyze the scenario of HIV-associated lymphoma.

Materials And Methods: This was a retrospective observational study conducted at our center, on consecutive patients diagnosed with HIV-associated lymphoma, from January 2008 to December 2012.

Results: A total of 44 patients were diagnosed with HIV-associated lymphoma, of which 18 opted for treatment. There were 11 males and 7 females in the study population. Median interval from the diagnosis of HIV infection to diagnosis of lymphoma was 18 months. Median CD4 count at the time of lymphoma diagnosis was 218/mm(3). Five patients had Hodgkin's lymphoma, and the rest had non-Hodgkin's lymphoma. Five out of 18 (28%) patients in the present study expired during treatment. Ten (55.5%) patients are alive and lymphoma free, with a median follow up of 18 months.

Conclusions: More than half of our treated patients are lymphoma free with a median follow up of 18 months; hence treatment of patients with HIV-associated lymphoma should be encouraged.

Citing Articles

Declining incidence and improving survival of ocular and orbital lymphomas in the US between 1995 and 2018.

Alfaar A, Yousef Y, Wilson M, Hassanain O, Kakkassery V, Moustafa M Sci Rep. 2024; 14(1):7886.

PMID: 38570585 PMC: 10991268. DOI: 10.1038/s41598-024-58508-7.

An Indian Perspective on HIV-associated Lymphomas.

Barta S N Am J Med Sci. 2013; 5(7):438-9.

PMID: 24020056 PMC: 3759074.

References

Beral V, Peterman T, Berkelman R, Jaffe H . AIDS-associated non-Hodgkin lymphoma. Lancet. 1991; 337(8745):805-9. DOI: 10.1016/0140-6736(91)92513-2. View

Kaplan L, Straus D, Testa M, Von Roenn J, Dezube B, Cooley T . Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997; 336(23):1641-8. DOI: 10.1056/NEJM199706053362304. View

Ziegler J, Beckstead J, Volberding P, Abrams D, Levine A, LUKES R . Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med. 1984; 311(9):565-70. DOI: 10.1056/NEJM198408303110904. View

Hoffmann C, Chow K, Wolf E, Faetkenheuer G, Stellbrink H, van Lunzen J . Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol. 2004; 125(4):455-62. DOI: 10.1111/j.1365-2141.2004.04934.x. View

Ribera J, Oriol A, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A . Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2007; 140(4):411-9. DOI: 10.1111/j.1365-2141.2007.06943.x. View

Little R, Pittaluga S, Grant N, Steinberg S, Kavlick M, Mitsuya H . Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003; 101(12):4653-9. DOI: 10.1182/blood-2002-11-3589. View

Cote T, Biggar R, Rosenberg P, Devesa S, Percy C, Yellin F . Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer. 1997; 73(5):645-50. DOI: 10.1002/(sici)1097-0215(19971127)73:5<645::aid-ijc6>3.0.co;2-x. View

Dhir A, Sawant S . Malignancies in HIV: the Indian scenario. Curr Opin Oncol. 2008; 20(5):517-21. DOI: 10.1097/CCO.0b013e32830a4c87. View

Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet F . Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001; 98(8):2339-44. DOI: 10.1182/blood.v98.8.2339. View

10.

Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B . Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001; 19(8):2171-8. DOI: 10.1200/JCO.2001.19.8.2171. View

11.

Levine A, Tulpule A, Espina B, Sherrod A, Boswell W, Lieberman R . Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol. 2004; 22(13):2662-70. DOI: 10.1200/JCO.2004.10.093. View

12.

Woldemedhin B, Wabe N . The Reason for Regimen Change Among HIV/AIDS Patients Initiated on First Line Highly Active Antiretroviral Therapy in Southern Ethiopia. N Am J Med Sci. 2012; 4(1):19-23. PMC: 3289485. DOI: 10.4103/1947-2714.92898. View

13.

Venkatesh K, Saghayam S, Devaleenal B, Poongulali S, Flanigan T, Mayer K . Spectrum of malignancies among HIV-infected patients in South India. Indian J Cancer. 2012; 49(1):176-80. PMC: 5592840. DOI: 10.4103/0019-509X.98947. View

14.

Chow K, Mitrou P, Geduldig K, Helm E, Hoelzer D, Brodt H . Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma. 2001; 41(1-2):105-16. DOI: 10.3109/10428190109057959. View

15.

Lim S, Karim R, Nathwani B, Tulpule A, Espina B, Levine A . AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005; 23(19):4430-8. DOI: 10.1200/JCO.2005.11.973. View

16.

Levine A . Lymphoma complicating immunodeficiency disorders. Ann Oncol. 1994; 5 Suppl 2:29-35. DOI: 10.1093/annonc/5.suppl_2.s29. View

17.

Dunleavy K, Little R, Pittaluga S, Grant N, Wayne A, Carrasquillo J . The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010; 115(15):3017-24. PMC: 2858473. DOI: 10.1182/blood-2009-11-253039. View

18.

Osazuwa F, Dirisu J, Okuonghae P . Early determination of human immunodeficiency virus status by routine voluntary counseling and testing in benin city, Nigeria. N Am J Med Sci. 2012; 4(2):99-103. PMC: 3296328. DOI: 10.4103/1947-2714.93378. View

19.

Harnly M, Swan S, Holly E, Kelter A, Padian N . Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS). Am J Epidemiol. 1988; 128(2):261-7. DOI: 10.1093/oxfordjournals.aje.a114966. View

20.

Kaplan L, Lee J, Ambinder R, Sparano J, Cesarman E, Chadburn A . Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005; 106(5):1538-43. PMC: 1895225. DOI: 10.1182/blood-2005-04-1437. View